WHAT IS THE BEST TREATMENT FOR ACUTE PROMYELOCYTIC LEUKEMIA

被引：9

作者：

AVVISATI, G

PETTI, MC

MANDELLI, F

机构：

[1] Hematology, Department of Human Biopathology, University La Sapienza, Rome

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷

关键词：

ACUTE PROMYELOCYTIC LEUKEMIA; COAGULOPATHY; MOLECULAR BIOLOGY; CHEMOTHERAPY; MAINTENANCE TREATMENT; ALL-TRANS-RETINOIC ACID TREATMENT;

D O I：

10.3109/10428199309064259

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The modern treatment of acute myelogenous leukemia (AML), consists of a polychemotherapeutic induction treatment followed by a post-remission therapy of variable intensity and duration and acute promyelocytic leukemia (APL) does not differ from this behavior. However, differently from the other AML subtypes, APL shows a high response rate to induction monochemotherapies with anthracycline drugs. This high response rate to anthracycline monochemotherapies is very peculiar of APL. Moreover, it has been suggested that maintanance treatment regimens incorporating the drugs Methotrexate and 6-Mercaptopurine, two drugs generally not utilized in the post-remission treatment of other AML subtypes, may be effective in prolonging the leukemia-free survival of APL. Furthermore, the results firstly obtained by a Chinese group in 1988 by using the vitamin A derivative all-trans retinoic acid (ATRA) have been successively confirmed by several other groups in the world. Therefore, at present the all-trans retinoic acid appears to be the best CR inducer in APL. However, these CRs are short lasting when maintained with ATRA alone and eventually all patients relapse. As a consequence, patients achieving CR with ATRA still require intensive post-remission chemotherapy to maintain the CR. As for bone marrow transplantation procedures, it is our opinion that they do not represent the treatment of choice of APL in first CR considering the very good results obtained with standard pharmacological approaches. In conclusion, only future randomized prospective trials will clarify which, among the several proposed therapeutic approaches, should be preferred in this very peculiar subtype of AML.

引用

页码：29 / 35

页数：7

共 52 条

[1] Avvisati G., ten Cate J.W., Mandelli F., The coagulopathy in acute promyelocytic leukemia: DIC, Hemostasis and Cancer, pp. 91-100, (1987)
[2] Tallman M.S., Kwaan H.C., Reassessing the hemostatic disorder associated with acute promyelocytic leukemia, Blood, 79, pp. 543-553, (1992)
[3] Avvisati G., Mele A., Stazi M.A., Vegna M.L., Pas-Quini P., Mandelli F., Epidemiology of acute promyelocytic leukemia in Italy, Ann. Oncol., 2, pp. 405-498, (1991)
[4] Avvisati G., ten Cate J.W., Sturk A., Lamping R., Petti M.C., Mandelli F., Acquired alpha 2–antiplasmin deficiency in acute promyelocytic leukaemia, Br. J. Haematol., 70, pp. 43-48, (1988)
[5] San Miguel J.F., Gonzales M., Canizo M.C., Auta J.P., Zola H., Lopez-Borrasca A., Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification, Br. J. Haematol., 64, pp. 547-560, (1986)
[6] Stone R.M., Maguire M., Goldberg M.A., Antin J.H., Rosenthal D.S., Mayer R.J., Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients, Blood, 71, pp. 690-696, (1988)
[7] De Rossi G., Avvisati G., Coluzzi S., Fenu S., Lo Coco F., Lopez M., Nanni M., Pasqualetti D., Mandelli F., Immunological definition of acute promyelocytic leukemia (FAB M3): a study of 39 cases, Eur. J. Haematol., 67, pp. 168-171, (1990)
[8] Lo Coco F., Avvisati G., Diverio D., Biondi A., Pandolfi P.P., Alcalay M., De Rossi G., Petti M.C., Cantu-Rajnoldi A., Pasqualetti D., Nanni M., Fenu S., Frontani M., Mandelli F., Rearrangements of the RAR-α gene in acute promyelocytic leukaemia: correlations with morphology and immunophenotype, Br. J. Haematol., 78, pp. 494-499, (1991)
[9] Bennet J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., Sultan C., Proposal for the classification of the acute leukemias. French-American-British (FAB) Cooperative Group, Br. J. Haematol., 33, pp. 451-458, (1976)
[10] Krause J.R., Stolc V., Kaplan S.S., Penchansky L., Microgranular promyelocytic leukemia: a multi parameter examination, Am. J. Hematol., 30, pp. 158-163, (1989)

← 1 2 3 4 5 6 →